Catalyst Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 102.69 million compared to USD 57.24 million a year ago. Net loss was USD 30.76 million compared to net income of USD 22.75 million a year ago. Basic loss per share from continuing operations was USD 0.29 compared to basic earnings per share from continuing operations of USD 0.22 a year ago. Diluted loss per share from continuing operations was USD 0.29 compared to diluted earnings per share from continuing operations of USD 0.2 a year ago.
For the nine months, revenue was USD 287.64 million compared to USD 153.45 million a year ago. Net income was USD 36.57 million compared to USD 57.61 million a year ago. Basic earnings per share from continuing operations was USD 0.34 compared to USD 0.56 a year ago. Diluted earnings per share from continuing operations was USD 0.32 compared to USD 0.52 a year ago.